Lymphoproliferative Disorders
Information
- Disease name
- Lymphoproliferative Disorders
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02663297 | Active, not recruiting | Phase 1 | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | July 15, 2016 | January 2037 |
| NCT04309084 | Active, not recruiting | Phase 1 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | May 12, 2020 | April 30, 2023 |
| NCT00028418 | Completed | Phase 1 | Clofarabine in Chronic Lymphocytic Leukemia | February 1999 | March 2004 |
| NCT00048412 | Completed | Phase 1/Phase 2 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | June 2000 | November 12, 2004 |
| NCT00058604 | Completed | Phase 1 | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | January 2001 | December 2008 |
| NCT00063648 | Completed | Phase 1 | Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant | May 2002 | December 2007 |
| NCT00068146 | Completed | Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma | September 19, 2002 | November 26, 2012 | |
| NCT03744676 | Completed | Phase 2 | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | November 29, 2018 | September 22, 2023 |
| NCT03397706 | Completed | Phase 1/Phase 2 | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies | March 29, 2018 | May 4, 2023 |
| NCT02973113 | Completed | Phase 1 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | February 16, 2016 | July 11, 2020 |
| NCT00001438 | Completed | Phase 2 | A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes | June 1995 | December 2000 |
| NCT06042400 | Completed | N/A | Trial of Written Exposure for Metastatic Cancer Patients (EASE) | April 18, 2022 | September 21, 2023 |
| NCT00002153 | Completed | Phase 1 | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders | ||
| NCT01728402 | Enrolling by invitation | Pathogenesis of Hematologic Malignancies | September 2008 | ||
| NCT02822495 | No longer available | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies | |||
| NCT05001386 | Not yet recruiting | N/A | In Vitro Drug Sensitivity Testing of Fresh Human Samples | March 2022 | March 2025 |
| NCT03939585 | Not yet recruiting | Phase 1 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT | June 1, 2024 | June 1, 2026 |
| NCT05969821 | Not yet recruiting | Clonal Hematopoiesis of Immunological Significance | September 2023 | September 2043 | |
| NCT05718986 | Not yet recruiting | Familial B-cell Lymphoproliferative Disorders | June 2024 | December 2040 | |
| NCT06271252 | Recruiting | Phase 1 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | April 3, 2024 | April 12, 2028 |
| NCT02690545 | Recruiting | Phase 1/Phase 2 | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | August 26, 2016 | August 26, 2040 |
| NCT03663933 | Recruiting | Phase 2 | Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation | September 4, 2018 | January 1, 2031 |
| NCT03922724 | Recruiting | Phase 2 | Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | April 18, 2019 | June 30, 2029 |
| NCT00131014 | Recruiting | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies | August 9, 2004 | January 2033 | |
| NCT04339777 | Recruiting | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity | September 22, 2020 | November 30, 2027 |
| NCT04554914 | Recruiting | Phase 2 | A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases | July 14, 2021 | May 2029 |
| NCT04858256 | Recruiting | Phase 2 | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | March 29, 2023 | November 2028 |
| NCT05770037 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers | December 18, 2023 | October 2029 |
| NCT05770102 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | October 25, 2023 | October 2029 |
| NCT05770544 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | June 2024 | October 2029 |
| NCT05803616 | Recruiting | Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders | May 23, 2022 | December 31, 2025 | |
| NCT05898789 | Recruiting | N/A | Virtual Rehabilitation for Cancer Survivors | July 7, 2023 | February 2025 |
| NCT02579967 | Recruiting | Phase 2 | Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies | November 19, 2015 | December 21, 2028 |
| NCT03394365 | Recruiting | Phase 3 | Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | December 29, 2017 | June 2027 |
| NCT03602157 | Recruiting | Phase 1 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | December 12, 2018 | September 30, 2041 |
| NCT00123942 | Terminated | Phase 1 | Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease | April 2004 | |
| NCT03601819 | Terminated | Phase 1 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | May 15, 2019 | July 17, 2020 |
| NCT00992732 | Terminated | Phase 2 | Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders | May 2010 | |
| NCT00579111 | Terminated | Phase 1/Phase 2 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | June 2007 | October 2010 |
| NCT02505789 | Unknown status | Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients | May 2013 | November 2018 | |
| NCT01186224 | Unknown status | N/A | Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) | May 2010 | May 2012 |
| NCT03373019 | Unknown status | Phase 2 | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | December 21, 2017 | March 1, 2021 |
| NCT05155215 | Unknown status | Phase 1/Phase 2 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | December 31, 2021 | February 28, 2023 |
| NCT03340155 | Unknown status | N/A | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases | October 30, 2017 | October 2022 |
| NCT04734470 | Unknown status | Expression of CD19 Complex in Lymphoproliferative Disorders | March 2021 | April 2023 | |
| NCT00968461 | Withdrawn | Phase 1 | Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders | May 2013 | |
| NCT05431179 | Withdrawn | Phase 3 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | March 2023 | December 2026 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008232